Literature DB >> 27698864

Soluble purified recombinant C2ORF40 protein inhibits tumor cell growth in vivo by decreasing telomerase activity in esophageal squamous cell carcinoma.

Linwei Li1, Xiaoyan Li1, Wenyu Wang1, Tianhui Gao1, Yun Zhou1, Shixin Lu2.   

Abstract

The chromosome 2 open reading frame 40 (C2ORF40) gene is a candidate tumor suppressor gene for a variety of tumors. Previous results by the present authors revealed that the C2ORF40 protein is a secreted protein. However, the exact biological function of secreted C2ORF40 protein in carcinogenesis has not been thoroughly investigated. In the present study, the signal peptide sequence of the C2ORF40 cDNA was initially removed to produce secreted recombinant human C2ORF40 protein (rhC2ORF40). Soluble rhC2ORF40 was successfully expressed and purified, which was evaluated for the first time, to the best of our knowledge, for tumor-suppressing function in vivo in esophageal cancer. The present results revealed that soluble purified rhC2ORF40 was concentrated with a purity of >95%. Furthermore, rhC2ORF40 inhibited esophageal cancer cell growth in vivo in a dose-dependent manner compared with a control group (P<0.05). In addition, the present study demonstrated for the first time that rhC2ORF40 decreased telomerase activity using telomeric repeat amplification protocol-enzyme-linked immunosorbent assay (P<0.05), without affecting the expression levels of telomerase-component RNA (P>0.05), as shown with polymerase chain reaction. Overall, the present results demonstrated that soluble rhC2ORF40 inhibited tumor cell growth in vivo by decreasing telomerase activity in esophageal squamous cell carcinoma. Therefore, soluble rhC2ORF40 with a high purity and biological activity may be a potential biological therapy drug for esophageal cancer.

Entities:  

Keywords:  biological therapy; esophageal cancer; rhC2ORF40; telomerase; tumor growth

Year:  2016        PMID: 27698864      PMCID: PMC5038444          DOI: 10.3892/ol.2016.4935

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  36 in total

1.  Downregulation of telomerase activity by diclofenac and curcumin is associated with cell cycle arrest and induction of apoptosis in colon cancer.

Authors:  Chandan Rana; Honit Piplani; Vivek Vaish; Bimla Nehru; S N Sanyal
Journal:  Tumour Biol       Date:  2015-03-06

2.  Esophageal cancer related gene 4 (ECRG4) is a marker of articular chondrocyte differentiation and cartilage destruction.

Authors:  Yun Hyun Huh; Je-Hwang Ryu; Sun Shin; Dong-Uk Lee; Siyoung Yang; Kyung-Shin Oh; Churl-Hong Chun; Jeong-Keun Choi; Woo Keun Song; Jang-Soo Chun
Journal:  Gene       Date:  2009-09-06       Impact factor: 3.688

3.  ECRG4 is a negative regulator of caspase-8-mediated apoptosis in human T-leukemia cells.

Authors:  Junichi Matsuzaki; Toshihiko Torigoe; Yoshihiko Hirohashi; Kenjiro Kamiguchi; Yasuaki Tamura; Tomohide Tsukahara; Terufumi Kubo; Akari Takahashi; Emiri Nakazawa; Eri Saka; Kazuyo Yasuda; Shuji Takahashi; Noriyuki Sato
Journal:  Carcinogenesis       Date:  2012-03-12       Impact factor: 4.944

4.  Esophageal cancer-related gene-4 (ECRG4) interactions with the innate immunity receptor complex.

Authors:  Sonia Podvin; Xitong Dang; Morgan Meads; Arwa Kurabi; Todd Costantini; Brian P Eliceiri; Andrew Baird; Raul Coimbra
Journal:  Inflamm Res       Date:  2014-12-16       Impact factor: 4.575

5.  C2ORF40 suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genes.

Authors:  Jing Lu; Mingxin Wen; Yurong Huang; Xiuquan He; Yunshan Wang; Qi Wu; Zengchun Li; Andres Castellanos-Martin; Mar Abad; Juan J Cruz-Hernandez; Cesar A Rodriguez; Jesús Pérez-Losada; Jian-Hua Mao; Guangwei Wei
Journal:  Epigenetics       Date:  2013-04-26       Impact factor: 4.528

6.  Expression of ECRG4 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma.

Authors:  Yoichiro Mori; Hideyuki Ishiguro; Yoshiyuki Kuwabara; Masahiro Kimura; Akira Mitsui; Horoki Kurehara; Ryota Mori; Keisuke Tomoda; Ryo Ogawa; Takeyasu Katada; Koshiro Harata; Yoshitaka Fujii
Journal:  Oncol Rep       Date:  2007-10       Impact factor: 3.906

7.  Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo.

Authors:  Lin-Wei Li; Xi-Ying Yu; Yang Yang; Chun-Peng Zhang; Li-Ping Guo; Shih-Hsin Lu
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

8.  Expression of ECRG4, a novel esophageal cancer-related gene, downregulated by CpG island hypermethylation in human esophageal squamous cell carcinoma.

Authors:  Chun-Mei Yue; Da-Jun Deng; Mei-Xia Bi; Li-Ping Guo; Shih-Hsin Lu
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

9.  Ecrg4 expression and its product augurin in the choroid plexus: impact on fetal brain development, cerebrospinal fluid homeostasis and neuroprogenitor cell response to CNS injury.

Authors:  Ana Maria Gonzalez; Sonia Podvin; Shuh-Yow Lin; Miles C Miller; Hannah Botfield; Wendy E Leadbeater; Andrew Roberton; Xitong Dang; Stuart E Knowling; Elena Cardenas-Galindo; John E Donahue; Edward G Stopa; Conrad E Johanson; Raul Coimbra; Brian P Eliceiri; Andrew Baird
Journal:  Fluids Barriers CNS       Date:  2011-01-18

10.  Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer.

Authors:  Renaud Sabatier; Pascal Finetti; José Adelaide; Arnaud Guille; Jean-Paul Borg; Max Chaffanet; Lydie Lane; Daniel Birnbaum; François Bertucci
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

View more
  1 in total

1.  Identification of Differentially Expressed Genes Induced by Aberrant Methylation in Oral Squamous Cell Carcinomas Using Integrated Bioinformatic Analysis.

Authors:  Xiaoqi Zhang; Hao Feng; Dongfang Li; Shanshan Liu; Norio Amizuka; Minqi Li
Journal:  Int J Mol Sci       Date:  2018-06-07       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.